Arnold & Porter Advises Norgine on Acquisition of SETOFILM®

The London office of Arnold & Porter has advised European specialty pharmaceutical company Norgine B.V. (Norgine) on the acquisition by its wholly owned subsidiary, SpePharm A.G., of SETOFILM^® in Europe, Australia and New Zealand from APR Applied Pharma Research s.a. (APR).

SETOFILM^® is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting in adults and children aged 6 months or older, for radiotherapy-induced nausea and vomiting in adults and for post-operative nausea and vomiting in adults and children aged 4 years or older. It is the first prescription-only medicine developed as an orodispersible film formulation to be registered in Europe.

Norgine previously marketed SETOFILM^® in selected European markets under a license agreement with APR but this transaction will enable Norgine to help more patients across a broader territory.

The London team included Life Sciences Regulatory and Commercial Contracts partner Ewan Townsend, Corporate partner Jeremy Willcocks and Corporate associate Tom Wilson.